Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma Nov 07, 2024
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea Nov 04, 2024
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference Oct 25, 2024
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference Oct 03, 2024
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements Sep 20, 2024
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 Sep 16, 2024
